CME director awarded 645 fully vested shares

GEPSMAN MARTIN J reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

GEPSMAN MARTIN J reported acquisition or exercise transactions in this Form 4 filing.

CME Group Inc. director Martin J. Gepsman received a grant of 645 shares of Class A common stock on June 25, 2026. The shares were issued at an indicated value of $225.00 per share as part of the company’s annual equity compensation program for non-employee directors.

After this award, Gepsman directly holds 25,644 Class A shares. According to the disclosure, the granted shares are fully vested upon issuance and are not subject to any vesting conditions, highlighting that this is a compensation-related equity grant rather than an open-market purchase.

Insider Trade Summary

Grant/Award: 645 shares

Grant/Award 1 txn

Insider GEPSMAN MARTIN J

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock Class A	645	$225.00	$145K

Holdings After Transaction: Common Stock Class A — 25,644 shares (Direct)

Footnotes (1)

1. F1. Represents a grant of fully vested shares of Class A Common Stock issued to the Reporting Person as part of the Issuer's annual equity compensation program for non-employee directors under the CME Group Director Stock Plan. These shares are not subject to any vesting conditions.

Key Figures

Shares granted: 645 shares Grant value per share: $225.00 per share Total shares after transaction: 25,644 shares

3 metrics

Shares granted 645 shares Class A common stock grant on June 25, 2026

Grant value per share $225.00 per share Reported award valuation for Class A grant

Total shares after transaction 25,644 shares Director’s direct Class A holdings post-award

Key Terms

Form 4, Class A Common Stock, annual equity compensation program, non-employee directors, +1 more

5 terms

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Class A Common Stock financial

"Represents a grant of fully vested shares of Class A Common Stock"

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

annual equity compensation program financial

"issued to the Reporting Person as part of the Issuer's annual equity compensation program"

non-employee directors financial

"equity compensation program for non-employee directors under the CME Group Director Stock Plan"

Non-employee directors are board members who do not work for the company as salaried employees and usually do not hold day-to-day management roles. They act like outside referees or independent coaches, providing oversight, asking tough questions, and protecting shareholders’ interests; investors care because these directors help ensure management is accountable, reduce conflicts of interest, and influence decisions that affect company strategy and long-term value.

CME Group Director Stock Plan financial

"for non-employee directors under the CME Group Director Stock Plan"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did CME (CME) director Martin Gepsman report?

Director Martin J. Gepsman reported receiving 645 shares of CME Class A common stock as an equity award. The grant is part of the annual compensation program for non-employee directors and represents a compensation-related acquisition, not an open-market stock purchase.

At what value were the CME (CME) shares granted to director Martin Gepsman?

The 645 Class A shares granted to Martin Gepsman were reported at $225.00 per share. This figure reflects the award valuation used in the filing and helps investors gauge the dollar value of the equity compensation provided to this non-employee director.

How many CME (CME) shares does Martin Gepsman hold after this Form 4 transaction?

After the reported grant, Martin Gepsman directly holds 25,644 shares of CME Class A common stock. This total includes the 645 fully vested shares awarded under the director stock plan as part of his annual equity compensation package.

Are the CME (CME) shares granted to Martin Gepsman subject to vesting conditions?

The 645 Class A shares granted to Martin Gepsman are fully vested immediately. The filing states they are issued under the CME Group Director Stock Plan and are not subject to any vesting conditions, meaning he has full rights to the shares upon grant.

Is Martin Gepsman’s CME (CME) transaction an open-market stock purchase?

No. The filing describes the transaction as a grant or award acquisition, not an open-market purchase. The 645 shares were issued as part of CME Group’s annual equity compensation program for non-employee directors under the CME Group Director Stock Plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/29/2026 - 04:30 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GEPSMAN MARTIN J

(Last) (First) (Middle)

20 S. WACKER DRIVE

(Street)

CHICAGO ILLINOIS 60606

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CME GROUP INC. [ CME ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock Class A	06/25/2026		A(1)		645	A	$225	25,644	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a grant of fully vested shares of Class A Common Stock issued to the Reporting Person as part of the Issuer's annual equity compensation program for non-employee directors under the CME Group Director Stock Plan. These shares are not subject to any vesting conditions.

Remarks:

	/s/ Elizabeth Hensen, as Attorney-in-Fact for Martin J. Gepsman	06/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)